The proposed intervention will be administration of empagliflozin at a standard dose of 10 mg
daily for a period of 12 months. Patients with diagnosed diabetes will be excluded from the
study. Patients (n = 250) will be randomized in a double-blind fashion to empagliflozin or
placebo group. The primary endpoint of the study will be the change in peak oxygen uptake
(VO2 max) measured in a cardiopulmonary exercise test. VO2max is an objective indicator of
physical performance and will be evaluated before and after empagliflozin or placebo
treatment.
Phase:
Phase 3
Details
Lead Sponsor:
Institute of Cardiology, Warsaw, Poland
Collaborators:
Medical University of Bialystok University of Eastern Finland VU University Medical Center